{
    "id": 2540,
    "fullName": "RB1 positive",
    "impact": "unknown",
    "proteinEffect": "unknown",
    "geneVariantDescriptions": [
        {
            "description": "RB1 positive indicates the presence of the RB1 gene, mRNA, and/or protein.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "non-specific",
    "gene": {
        "id": 5925,
        "geneSymbol": "RB1",
        "terms": [
            "RB1",
            "OSRC",
            "p105-Rb",
            "p110-RB1",
            "pp110",
            "PPP1R130",
            "pRb",
            "RB"
        ]
    },
    "variant": "positive",
    "createDate": "11/04/2014",
    "updateDate": "05/15/2018",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 9353,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Ibrance (palbociclib) inhibited proliferation of RB1-proficient glioblastoma cell lines in culture and inhibited tumor growth in intracranial cell line xenograft models (PMID: 20354191).",
            "molecularProfile": {
                "id": 2395,
                "profileName": "RB1 positive"
            },
            "therapy": {
                "id": 850,
                "therapyName": "Palbociclib",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 4520,
                    "pubMedId": 20354191,
                    "title": "Pharmacologic inhibition of cyclin-dependent kinases 4 and 6 arrests the growth of glioblastoma multiforme intracranial xenografts.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/20354191"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6864,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Ibrance (palbociclib) inhibited Rb1 phosphorylation in tumor tissues and improved survival in patient-derived intracranial xenograft models of medulloblastoma (PMID: 27012813).",
            "molecularProfile": {
                "id": 2395,
                "profileName": "RB1 positive"
            },
            "therapy": {
                "id": 850,
                "therapyName": "Palbociclib",
                "synonyms": null
            },
            "indication": {
                "id": 50902,
                "name": "medulloblastoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5910,
                    "pubMedId": 27012813,
                    "title": "DiSCoVERing Innovative Therapies for Rare Tumors: Combining Genetically Accurate Disease Models with In Silico Analysis to Identify Novel Therapeutic Targets.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27012813"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1680,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I clinical trial, Kisqali (ribociclib) demonstrated safety and preliminary efficacy in patients with RB1-positive solid tumors and lymphomas, resulting in partial responses in 2.3% (3/132) of patients and stable disease in 32.6% (41/132) of patients, including 8 patients demonstrating stable disease for greater than 6 months (PMID: 27542767, PMID: 24795392).",
            "molecularProfile": {
                "id": 2395,
                "profileName": "RB1 positive"
            },
            "therapy": {
                "id": 790,
                "therapyName": "Ribociclib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 1549,
                    "pubMedId": 24795392,
                    "title": "Molecular pathways: CDK4 inhibitors for cancer therapy.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24795392"
                },
                {
                    "id": 1781,
                    "pubMedId": null,
                    "title": "A phase I study of the single-agent CDK4/6 inhibitor LEE011 in pts with advanced solid tumors and lymphomas.",
                    "url": "http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/2528"
                },
                {
                    "id": 7226,
                    "pubMedId": 27542767,
                    "title": "A Phase I Study of the Cyclin-Dependent Kinase 4/6 Inhibitor Ribociclib (LEE011) in Patients with Advanced Solid Tumors and Lymphomas.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27542767"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16790,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, alternating sequential treatment with Ibrance (palbociclib) and Taxol (paclitaxel) resulted in a median progression-free survival (mPFS) of 209 days in patients with Rb1-positive breast cancer, with a mPFS of 802 days and a clinical benefit rate of 55.6% (5/9) at the recommended phase II dose (PMID: 30635336; NCT01320592).",
            "molecularProfile": {
                "id": 2395,
                "profileName": "RB1 positive"
            },
            "therapy": {
                "id": 8198,
                "therapyName": "Paclitaxel + Palbociclib",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 14913,
                    "pubMedId": 30635336,
                    "title": "Combination Paclitaxel and Palbociclib: Results of a Phase I Trial in Advanced Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30635336"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1682,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II clinical trial, Ibrance (palbociclib) demonstrated efficacy and improved progression free survival in patients with CDK4 amplified liposarcoma with expression of RB1 (PMID: 23569312).",
            "molecularProfile": {
                "id": 16567,
                "profileName": "CDK4 amp RB1 pos"
            },
            "therapy": {
                "id": 850,
                "therapyName": "Palbociclib",
                "synonyms": null
            },
            "indication": {
                "id": 5693,
                "name": "adult liposarcoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 1787,
                    "pubMedId": 23569312,
                    "title": "Phase II trial of the CDK4 inhibitor PD0332991 in patients with advanced CDK4-amplified well-differentiated or dedifferentiated liposarcoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23569312"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 19400,
            "approvalStatus": "Phase 0",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase 0 trial, Kisqali (ribociclib) demonstrated good CNS penetration and inhibited Rb1 phoaphorylation and tumor cell proliferation, resulted in a median progression-free survival of 9.7 week and an overall survival of 7.8 months in patients (n=6) with recurrent glioblastoma with intact Rb1 expression and harboring deletion of CDKN2A or amplification of CDK4 or CDK6 (PMID: 31285369; NCT02933736).",
            "molecularProfile": {
                "id": 16567,
                "profileName": "CDK4 amp RB1 pos"
            },
            "therapy": {
                "id": 790,
                "therapyName": "Ribociclib",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 16988,
                    "pubMedId": 31285369,
                    "title": "A Phase 0 Trial of Ribociclib in Recurrent Glioblastoma Patients Incorporating a Tumor Pharmacodynamic- and Pharmacokinetic-Guided Expansion Cohort.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31285369"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5886,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, G1T38 treatment resulted in growth inhibition in AR-negative, RB1-positive prostate cancer cell lines in culture (AACR, Cancer Res: April 2016; Volume 57, Abstract #2820).",
            "molecularProfile": {
                "id": 21980,
                "profileName": "AR neg RB1 pos"
            },
            "therapy": {
                "id": 3970,
                "therapyName": "G1T38",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5183,
                    "pubMedId": null,
                    "title": "Effects of a CDK 4/6 inhibitor, G1T38, in androgen receptor sensitive and resistant models of castrate resistant prostate cancer",
                    "url": "http://www.abstractsonline.com/Plan/ViewAbstract.aspx?mID=4017&sKey=12eab58f-9b3f-418d-ad0c-e55a553a95b9&cKey=90cf56d3-fe9d-4b4d-8477-6867a79402af&mKey=1d10d749-4b6a-4ab3-bcd4-f80fb1922267"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9355,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Ibrance (palbociclib) inhibited tumor growth and improved survival in patient-derived intracranial xenografts models of RB-proficient glioblastoma harboring homozygous deletion of the CDKN2A and CDKN2B (PMID: 20354191).",
            "molecularProfile": {
                "id": 26829,
                "profileName": "CDKN2A loss CDKN2B loss RB1 pos"
            },
            "therapy": {
                "id": 850,
                "therapyName": "Palbociclib",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4520,
                    "pubMedId": 20354191,
                    "title": "Pharmacologic inhibition of cyclin-dependent kinases 4 and 6 arrests the growth of glioblastoma multiforme intracranial xenografts.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/20354191"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15144,
            "approvalStatus": "Preclinical - Pdx & cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, treatment with Ibrance (palbociclib) resulted in growth inhibition of RB1-positive, estrogen-receptor positive breast cancer cells expressing ESR1-YAP1 in culture and inhibition of tumor growth in a RB1-positive, estrogen-receptor positive breast cancer patient-derived xenograft (PDX) model harboring ESR1-YAP1, which demonstrated reduced phosphorylation of Rb1 and decreased Ki67 levels (PMID: 30089255).",
            "molecularProfile": {
                "id": 30795,
                "profileName": "ESR1 - YAP1 RB1 pos"
            },
            "therapy": {
                "id": 850,
                "therapyName": "Palbociclib",
                "synonyms": null
            },
            "indication": {
                "id": 60075,
                "name": "estrogen-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 12690,
                    "pubMedId": 30089255,
                    "title": "Functional Annotation of ESR1 Gene Fusions in Estrogen Receptor-Positive Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30089255"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15145,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, treatment with Ibrance (palbociclib) resulted in growth inhibition of RB1-positive, estrogen-receptor positive breast cancer cells expressing ESR1-PCDH11X in culture (PMID: 30089255).",
            "molecularProfile": {
                "id": 30796,
                "profileName": "ESR1 - PCDH11X RB1 pos"
            },
            "therapy": {
                "id": 850,
                "therapyName": "Palbociclib",
                "synonyms": null
            },
            "indication": {
                "id": 60075,
                "name": "estrogen-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 12690,
                    "pubMedId": 30089255,
                    "title": "Functional Annotation of ESR1 Gene Fusions in Estrogen Receptor-Positive Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30089255"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19401,
            "approvalStatus": "Phase 0",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase 0 trial, Kisqali (ribociclib) demonstrated good CNS penetration and inhibited Rb1 phoaphorylation and tumor cell proliferation, resulted in a median progression-free survival of 9.7 week and an overall survival of 7.8 months in patients (n=6) with recurrent glioblastoma with intact Rb1 expression and harboring deletion of CDKN2A or amplification of CDK4 or CDK6 (PMID: 31285369; NCT02933736).",
            "molecularProfile": {
                "id": 32265,
                "profileName": "CDK6 amp RB1 pos"
            },
            "therapy": {
                "id": 790,
                "therapyName": "Ribociclib",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 16988,
                    "pubMedId": 31285369,
                    "title": "A Phase 0 Trial of Ribociclib in Recurrent Glioblastoma Patients Incorporating a Tumor Pharmacodynamic- and Pharmacokinetic-Guided Expansion Cohort.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31285369"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18282,
            "approvalStatus": "Phase III",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial (PALOMA-3), RB1 expression level did not correlate with response to addition of Ibrance (palbociclib) to Faslodex (fulvestrant) in patients with hormone receptor-positive, Erbb2 (Her2)-negative breast cancer, with hazard ratios for progression-free survival of Ibrance (palbociclib) versus placebo of 0.425 and 0.672 (p=0.123) in RB1 low and high expression groups, respectively (PMID: 30807234; NCT01942135).",
            "molecularProfile": {
                "id": 33100,
                "profileName": "ESR1 pos RB1 pos"
            },
            "therapy": {
                "id": 3205,
                "therapyName": "Fulvestrant + Palbociclib",
                "synonyms": null
            },
            "indication": {
                "id": 60080,
                "name": "Her2-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 16119,
                    "pubMedId": 30807234,
                    "title": "Cyclin E1 Expression and Palbociclib Efficacy in Previously Treated Hormone Receptor-Positive Metastatic Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30807234"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 18283,
            "approvalStatus": "Phase III",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial (PALOMA-3), RB1 expression level did not correlate with response to addition of Ibrance (palbociclib) to Faslodex (fulvestrant) in patients with hormone receptor-positive, Erbb2 (Her2)-negative breast cancer, with hazard ratios for progression-free survival of Ibrance (palbociclib) versus placebo of 0.425 and 0.672 (p=0.123) in RB1 low and high expression groups, respectively (PMID: 30807234; NCT01942135).",
            "molecularProfile": {
                "id": 33101,
                "profileName": "PGR pos RB1 pos"
            },
            "therapy": {
                "id": 3205,
                "therapyName": "Fulvestrant + Palbociclib",
                "synonyms": null
            },
            "indication": {
                "id": 60080,
                "name": "Her2-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 16119,
                    "pubMedId": 30807234,
                    "title": "Cyclin E1 Expression and Palbociclib Efficacy in Previously Treated Hormone Receptor-Positive Metastatic Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30807234"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 19403,
            "approvalStatus": "Phase 0",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase 0 trial, Kisqali (ribociclib) demonstrated good CNS penetration and inhibited Rb1 phoaphorylation and tumor cell proliferation, resulted in a median progression-free survival of 9.7 week and an overall survival of 7.8 months in patients (n=6) with recurrent glioblastoma with intact Rb1 expression and harboring deletion of CDKN2A or amplification of CDK4 or CDK6 (PMID: 31285369; NCT02933736).",
            "molecularProfile": {
                "id": 34074,
                "profileName": "CDKN2A del RB1 pos"
            },
            "therapy": {
                "id": 790,
                "therapyName": "Ribociclib",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 16988,
                    "pubMedId": 31285369,
                    "title": "A Phase 0 Trial of Ribociclib in Recurrent Glioblastoma Patients Incorporating a Tumor Pharmacodynamic- and Pharmacokinetic-Guided Expansion Cohort.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31285369"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 2395,
            "profileName": "RB1 positive",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 16567,
            "profileName": "CDK4 amp RB1 pos",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 21980,
            "profileName": "AR neg RB1 pos",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 26829,
            "profileName": "CDKN2A loss CDKN2B loss RB1 pos",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 30795,
            "profileName": "ESR1 - YAP1 RB1 pos",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 30796,
            "profileName": "ESR1 - PCDH11X RB1 pos",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 32262,
            "profileName": "CCND1 amp RB1 pos",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 32263,
            "profileName": "CCND2 amp RB1 pos",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 32264,
            "profileName": "CCND3 amp RB1 pos",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 32265,
            "profileName": "CDK6 amp RB1 pos",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 33100,
            "profileName": "ESR1 pos RB1 pos",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 33101,
            "profileName": "PGR pos RB1 pos",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 34074,
            "profileName": "CDKN2A del RB1 pos",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}